Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
i.e decrease » we decrease (Expand Search), sizes decrease (Expand Search), teer decrease (Expand Search)
Showing 1,021 - 1,040 results of 14,274 for search '(( significant increase decrease ) OR ( significant ((i.e decrease) OR (mean decrease)) ))', query time: 0.59s Refine Results
  1. 1021
    Annual number of outpatient visits in all eyes.

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1022
    Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye.

    Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1023
    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups.

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1024
    Time course of best-corrected visual acuity (BCVA) in all eyes.

    Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1025
    Annual number of outpatient visits in recurrence and non-recurrence groups.

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1026
    Time course of central retinal thickness (CRT) in all eyes.

    Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1027
    Annual treatment frequencies in all eyes.

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1028
    Annual treatment frequencies in recurrence and non-recurrence groups.

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1029
    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups.

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1030
    Preoperative background characteristics of the patients.

    Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1031
    Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>.

    Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 1032
    Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection.

    Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

    Published 2025
    Save to List
    Saved in:
  13. 1033
    The proportional change in maximum height for the five study groups.

    The proportional change in maximum height for the five study groups. by Teagan McMahon (20108036)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 1034
    Fig 6 -

    Fig 6 - by Teagan McMahon (20108036)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 1035
    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth.

    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

    Published 2025
    Save to List
    Saved in:
  16. 1036
    Mean lipid profile (mmol/L) upon completion of the experimental period.

    Mean lipid profile (mmol/L) upon completion of the experimental period. by Elsie D. Oduor (22521785)

    Published 2025
    Save to List
    Saved in:
  17. 1037
    Unique intestinal microbiota in healthy shrimp.

    Unique intestinal microbiota in healthy shrimp. by Lalitphan Kitsanayanyong (19353505)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1038
    Unique intestinal microbiota in diseased shrimp.

    Unique intestinal microbiota in diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1039
    Treatment of cancer cells with vitamin D3 induced death <i>a.</i>

    Treatment of cancer cells with vitamin D3 induced death <i>a.</i> by Vidya G. Bettada (22208808)

    Published 2025
    Save to List
    Saved in:
  20. 1040
    S1 File - Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic

    S1 File - Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic by Jelena Filimonovic (22305307)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: